ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January
ScripBayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
ScripWomen’s health remains a big area of unmet medical need and since women make up half the population, the commercial opportunity is enormous, but investment in therapeutics for women – whether for fema